Short answer: in clinical trials involving nearly 4,000 people, retatrutide’s side-effect profile looked broadly similar to other incretin drugs like semaglutide and tirzepatide, mostly gastrointestinal and mostly early. But “safe” is a bigger claim than the data can support yet. Two signals are new, the longest controlled data is about two years, and none of it applies to vials bought online. Here is what is known, what is not, and the one point almost every article on this topic gets wrong.
If you search “is retatrutide safe,” you will find two kinds of answers. Sellers tell you it is “well tolerated.” Worried headlines tell you it is untested. Both are lazy. The honest answer depends on what you mean by safe, for whom, for how long, and, crucially, made by whom.
How much safety data actually exists
Retatrutide (Lilly code LY3437943) has now been tested in several controlled trials. Here are the ones with public results:
| Trial | Phase | Population | People | Length | Status of results |
|---|---|---|---|---|---|
| Jastreboff et al. | 2 | Obesity | 338 | 48 weeks | Peer-reviewed (NEJM 2023) |
| Rosenstock et al. | 2 | Type 2 diabetes | 281 | 36 weeks | Peer-reviewed (Lancet 2023) |
| TRIUMPH-4 | 3 | Obesity + knee OA | 445 | 68 weeks | Company topline |
| TRIUMPH-1 | 3 | Obesity | 2,339 | 80 weeks (104 extension) | Topline + ADA 2026 |
| TRANSCEND-T2D-1 | 3 | Type 2 diabetes | 537 | 40 weeks | Published (Lancet 2026) |
That is close to 4,000 participants. For comparison, semaglutide now has years of real-world use across millions of patients, plus a dedicated cardiovascular outcomes trial. Retatrutide is roughly where semaglutide was before approval: promising, well studied in the short and medium term, and unknown beyond that.
The common side effects, by dose
The pattern is the one you would expect from an incretin drug: gastrointestinal effects, dose-dependent, mostly during the escalation phase. The biggest trial, TRIUMPH-1, reported:
| TRIUMPH-1 (80 weeks) | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhea | 25.2% | 34.1% | 32.0% | 13.5% |
| Constipation | 23.8% | 25.9% | 26.1% | 10.9% |
| Vomiting | 10.6% | 22.8% | 25.3% | 4.8% |
| Urinary tract infection | 7.5% | 8.8% | 8.4% | 5.3% |
| Dysesthesia | 5.1% | 12.3% | 12.5% | 0.9% |
| Stopped due to side effects | 4.1% | 6.9% | 11.3% | 4.9% |
In people with type 2 diabetes (TRANSCEND-T2D-1), rates were lower: nausea 26.5% and discontinuation 5.1% at 12 mg. In TRIUMPH-4, discontinuation for side effects reached 18.2% at 12 mg, and Lilly noted it was strongly linked to lower starting BMI, including people stopping because they felt they were losing too much weight.
What this means: at the top dose, about one in nine people in the largest trial quit because of side effects, versus one in twenty on placebo. That is not alarming for this drug class. It is not trivial either.
The two signals that are new
1. Dysesthesia
Dysesthesia is an unpleasant or abnormal sensation in the skin: tingling, burning, prickling or heightened sensitivity to touch. It appears in every retatrutide phase 3 trial reported so far, at rates well above placebo:
- TRIUMPH-1: up to 12.5% vs 0.9% on placebo
- TRIUMPH-4: up to 20.9% vs 0.7% on placebo
- TRANSCEND-T2D-1: up to 4.5% vs 0% on placebo
Lilly describes the events as generally mild to moderate, mostly resolving during treatment, and rarely leading to discontinuation. What has not been explained publicly is why it happens. It is not a prominent feature of semaglutide or tirzepatide, which suggests it may be linked to the glucagon component or to the speed of weight loss. Full publications should clarify this.
2. Heart rate
In the phase 2 obesity trial, resting heart rate rose in a dose-dependent way, peaked around week 24 and then declined. Small heart rate increases are a known effect of GLP-1-based drugs, but this is a signal researchers are watching closely given the glucagon receptor’s effects on the heart. Phase 3 heart rate data had not been detailed in the topline releases.
Class risks inherited from GLP-1 drugs
Because retatrutide activates the GLP-1 receptor, researchers assume it carries the same class-level concerns as semaglutide and tirzepatide until proven otherwise. The approved drugs in this class carry warnings for:
- Pancreatitis. Rare, but listed for every GLP-1 receptor agonist.
- Gallbladder problems, including gallstones, which are also linked to rapid weight loss in general.
- Thyroid C-cell tumours in rodents. Seen in animal studies of this class; relevance to humans is not established, but approved products carry a warning.
- Dehydration and kidney strain when vomiting or diarrhea is severe.
- Low blood sugar when combined with insulin or sulfonylureas.
- Delayed stomach emptying, which matters before surgery or anaesthesia.
Retatrutide-specific rates for the rare events (pancreatitis, gallbladder disease) have not been broken out in the phase 3 toplines. Those are exactly the numbers to look for when the full papers are published.
Does the third receptor add risk?
This is the question everyone asks. Retatrutide is the first drug in late-stage trials to activate GIP, GLP-1 and glucagon receptors. Glucagon is normally thought of as the hormone that raises blood sugar, so adding it sounds counterintuitive.
The logic is that glucagon also increases energy expenditure and fat burning in the liver, while the GLP-1 and GIP components keep blood sugar under control. The theoretical concerns are heart rate (see above), blood sugar regulation and effects on the liver.
So far the data on the liver has gone the other way from the worry. A phase 2 substudy published in Nature Medicine in 2024 reported large reductions in liver fat, with most participants on the higher doses reaching normal liver fat levels. And in people with type 2 diabetes, A1C fell by up to 2.0 percentage points in TRANSCEND-T2D-1, so the glucagon component did not undermine glucose control.
Fair summary: more receptors does not automatically mean more danger. But it does mean more ways for something unexpected to show up, and dysesthesia may be the first example.
What about muscle loss?
Any large weight loss includes some lean mass, whether it comes from diet, surgery or medication. In body-composition studies of semaglutide and tirzepatide, lean mass made up roughly a quarter to a third of total weight lost. With retatrutide producing even larger total losses, the absolute amount of lean tissue lost is a fair question. Detailed body-composition data from phase 3 has not yet been published. This is one of the most-watched open questions in the field, and why researchers are testing combinations with muscle-preserving compounds.
What nobody knows yet
- Anything beyond about two years. The longest controlled data is the 104-week TRIUMPH-1 extension.
- Cardiovascular outcomes. A dedicated cardiovascular trial is under way. Until it reports, nobody can say whether retatrutide reduces, increases or does not affect heart attacks and strokes.
- Rare events. Side effects that occur in 1 in 10,000 people do not show up in trials of 4,000. They appear after approval, in real-world use.
- Groups that were excluded. Trials generally excluded pregnancy, people with a history of pancreatitis, certain thyroid cancers, and serious heart, liver or kidney disease. Nothing is known about safety in those groups.
- What happens after stopping. Based on semaglutide and tirzepatide, substantial weight regain is likely. See mistake #10 in our retatrutide mistakes guide.
The point almost everyone gets wrong
Every number in this article was produced by Eli Lilly’s pharmaceutical retatrutide, manufactured under GMP conditions, injected at controlled doses, in screened participants, under medical monitoring. That is what “safety data” means.
None of it transfers automatically to a research-grade vial bought online. A research vial could be under-filled, degraded, contaminated or a different molecule entirely, and the trial data says nothing about any of those scenarios. This is true of every supplier, including TrueLabs, which is why our products are labelled for laboratory use only and backed by lot-specific COAs with mass spectrometry identity.
So the most accurate answer to “is retatrutide safe?” is this: Lilly’s retatrutide, in trials, looks broadly as tolerable as the drugs already on the market, with two new signals worth watching and long-term questions still open. Anything beyond that sentence is someone’s opinion.
If you are asking for yourself: semaglutide and tirzepatide are approved and prescribable in Canada, with years of real-world safety data. A doctor can tell you whether they fit, and whether a clinical trial might be an option.
View TrueLabs retatrutide (RT3) and its COA →
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
Is retatrutide safe?
In trials of nearly 4,000 people, retatrutide’s side effects were mostly gastrointestinal and broadly similar to other incretin drugs. Long-term safety beyond about two years, rare events and cardiovascular outcomes are not yet known, and it is not approved in Canada.
What are the most common side effects of retatrutide?
Nausea, diarrhea, constipation and vomiting. In TRIUMPH-1 at 12 mg, 42.4% reported nausea and 25.3% vomiting, compared with 14.8% and 4.8% on placebo.
What is retatrutide dysesthesia?
Dysesthesia is an abnormal skin sensation such as tingling, burning or sensitivity to touch. It was reported in up to 12.5% of participants in TRIUMPH-1 and up to 20.9% in TRIUMPH-4, generally mild to moderate.
Does retatrutide raise heart rate?
In the phase 2 obesity trial, resting heart rate increased in a dose-dependent way, peaked around week 24 and then declined. Detailed phase 3 heart rate data has not yet been published.
How many people stopped retatrutide because of side effects?
In TRIUMPH-1, 4.1%, 6.9% and 11.3% at 4, 9 and 12 mg, versus 4.9% on placebo. In TRIUMPH-4 the figure reached 18.2% at 12 mg.
Is retatrutide safer than tirzepatide?
There is no head-to-head trial, so nobody can say. Tirzepatide has far more real-world safety data. Retatrutide shows similar gastrointestinal effects plus a higher rate of dysesthesia.
Related reading
- Retatrutide in Canada: legal status and how to verify a supplier
- 10 costly retatrutide mistakes to avoid
- Retatrutide vs tirzepatide vs semaglutide
- Tirzepatide explained
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514–526. PubMed
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544. PubMed
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PubMed
- Eli Lilly and Company. TRIUMPH-1 and TRANSCEND-T2D-1 results presented at ADA 86th Scientific Sessions. Press release, June 6, 2026. Lilly
- Eli Lilly and Company. Retatrutide TRIUMPH-4 topline results. Press release, December 11, 2025. Lilly
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use, and nothing in this article is medical advice. If you have questions about weight-loss treatment, please talk to a doctor or pharmacist.